Interestingly, in a recent study of drug sensitivity in colorectal cancer for 16 cancer compounds, Schuette et al. 59 demonstrated experimentally that the sensitivity to EGFR inhibitors may be predicted using molecular biomarkers while they were unable to establish such a link for mTOR inhibitors. Here, EGFR is linked to colorectal cancer.